IgG4 antibodies against Bm14 as an evaluation tool of mass drug administration in a co-endemic area of Brugia timori and Wuchereria bancrofti

Djuardi, Yenny; Jannah, Insani Fitrahulil; Supali, Taniawati

doi:10.1016/j.actatropica.2021.106278

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same positive cutoff was selected for the anti-rBm14 and anti-rWb123 ELISA for consistency. This is similar to previously reported cutoffs for assays with Bm14 [ 16 ].…”

Section: Methodssupporting

confidence: 91%

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

et al. 2023

View full text Add to dashboard Cite

Background Lymphatic filariasis (LF) is a neglected tropical disease and a major cause of chronic disability. Improved diagnostic tests are needed because of long-term persistence of anti-filarial antibodies or circulating filarial antigenemia after treatments that clear microfilaremia. Here, we assess changes in levels of antibodies to the recombinant filarial antigens Wb-Bhp-1, Wb123, and Bm14 after anti-filarial treatment. Methodology/principal findings IgG4 antibodies to recombinant filarial antigens were assessed by ELISA. We tested serial plasma samples from a clinical trial in Papua New Guinea. Before treatment, 90%, 71% and 99% of participants had antibodies to Wb-Bhp-1, Wb123, and Bm14, respectively. Antibodies to Wb-Bhp-1 and Wb123, but not Bm14, were significantly higher in participants with persistent microfilaremia 24 months after treatment. Antibodies to all three antigens declined significantly by 60 months after treatment with ivermectin, diethylcarbamazine and albendazole despite circulating filarial antigen in 76% of participants. By 60 months follow up, antibodies to Wb-Bhp-1, Wb123, and Bm14 were detected in 17%, 7% and 90% of participants, respectively. Antibodies to Wb-Bhp-1 also declined more rapidly after treatment than antibodies to Bm14 in samples from a clinical trial conducted in Sri Lanka. We also tested archived serum samples from people living in filariasis-endemic communities in Egypt with different infection profiles. Antibodies to Wb-Bhp-1 were detected in 73% of microfilaremic people, 53% of amicrofilaremic people with circulating filarial antigen, and 17.5% of endemic individuals without microfilaria or circulating filarial antigen. Tests performed with legacy samples from India showed that few people with filarial lymphedema had antibodies to these recombinant antigens. Conclusions Antibodies to Wb-Bhp-1 and Wb123 are more closely correlated with persistent microfilaremia than circulating filarial antigenemia or antibodies to Bm14, and they clear more rapidly after anti-filarial treatment. Additional studies are needed to assess the value of Wb-Bhp-1 serology as a tool for determining the success of LF elimination efforts.

show abstract

“…The same positive cutoff was selected for the anti-rBm14 and anti-rWb123 ELISA for consistency. This is similar to previously reported cutoffs for assays with Bm14 [ 16 ].…”

Section: Methodssupporting

confidence: 91%

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The general outcome is that humans are living longer lives with improved access to more and better quality food, health care and hygiene. These benefits have arisen from the progress made in veterinary and human medicine, including advancements in diagnostic capacity (Djuardi et al 2022 ), anti-parasitic drugs (Tavul et al 2022 ), vaccines (Lightowlers et al 2021 ), and, more recently, bioengineering approaches to neutralise disease vectors (Wang et al 2021 ; Windbichler et al 2011 ). Conversely, this period of development has in parallel experienced ongoing negative changes to the natural environment in response to an ever-increasing demand of natural resources and developed space (Crippa et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Managing host-parasite interactions in humans and wildlife in times of global change

Wells

Flynn²

2022

Parasitol Res

View full text Add to dashboard Cite

Global change in the Anthropocene has modified the environment of almost any species on earth, be it through climate change, habitat modifications, pollution, human intervention in the form of mass drug administration (MDA), or vaccination. This can have far-reaching consequences on all organisational levels of life, including eco-physiological stress at the cell and organism level, individual fitness and behaviour, population viability, species interactions and biodiversity. Host-parasite interactions often require highly adapted strategies by the parasite to survive and reproduce within the host environment and ensure efficient transmission among hosts. Yet, our understanding of the system-level outcomes of the intricate interplay of within host survival and among host parasite spread is in its infancy. We shed light on how global change affects host-parasite interactions at different organisational levels and address challenges and opportunities to work towards better-informed management of parasite control. We argue that global change affects host-parasite interactions in wildlife inhabiting natural environments rather differently than in humans and invasive species that benefit from anthropogenic environments as habitat and more deliberate rather than erratic exposure to therapeutic drugs and other control efforts.

show abstract

“…Related to this, the BR test (mentioned earlier), also an IgG4 rapid test, showed a significant decrease in filariasis detection posttreatment and is used for evaluating the success of the mass drug administration in brugian filariasis areas. 15,16 A limitation of our study is the small number of samples, especially G2 and G4. In conclusion, the SsRapid showed an overall good performance compared with the two commercial IgG-ELISAs.…”

mentioning

confidence: 98%

Performance Assessment of a Lateral Flow Rapid Test (SsRapid®) Compared with Two Commercial ELISAs in Detecting Strongyloides Infection

Anuar

Rahumatullah

Samsudin

et al. 2023

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Approximately 600 million people worldwide are infected with Strongyloides stercoralis. Many diagnostic laboratories use serology to detect the infection. SsRapid® is a prototype IgG4 lateral flow test based on NIE recombinant protein. We compared SsRapid with two commercial IgG-ELISAs (Bordier and Euroimmun) using five sera groups (G1–5, N = 170). Healthy individuals from nonendemic areas (G1, N = 33) and Strongyloides larvae-positive patients (G2, N = 20) showed no significant difference (P > 0.05) among the three assays. The group of other parasitic infections (G3) showed that SsRapid results were more concordant with Bordier ELISA (73%, 35/48) than Euroimmun ELISA (65%, 31/48). In corticosteroid-treated cancer patients who were polymerase chain reaction–positive for Strongyloides (G4, N = 25), SsRapid showed a higher detection rate (28%, 7/25) than both ELISAs (4%, 1/25). Meanwhile, SsRapid showed significantly less infection prevalence among the endemic area population (G5) than the ELISAs. Overall, SsRapid showed good performance in detecting Strongyloides infection compared with the commercial IgG-ELISAs.

show abstract

IgG4 antibodies against Bm14 as an evaluation tool of mass drug administration in a co-endemic area of Brugia timori and Wuchereria bancrofti

Cited by 3 publications

References 23 publications

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

Managing host-parasite interactions in humans and wildlife in times of global change

Performance Assessment of a Lateral Flow Rapid Test (SsRapid®) Compared with Two Commercial ELISAs in Detecting Strongyloides Infection

Contact Info

Product

Resources

About